Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.44 |
| ▸ | CTSK | P43235 | 6/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15940941 | 0.91 | CTSL (0.54) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL31433016 | 0.79 | MEN1 (0.50) | LDHAALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15941163 | 0.78 | SMN1; SMN2 (0.53) | CTSSCTSKCTSBCTSLALDH1A1 | |
| SCHEMBL15940809 | 0.77 | KMT2A (0.47) | LDHAALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15941015 | 0.77 | KMT2A (0.47) | LDHAALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL2675118 | 0.75 | ACE (0.56) | CTSSCTSKCTSBCTSL | |
| SCHEMBL2675114 | 0.75 | ACE (0.56) | CTSSCTSKCTSBCTSL | |
| SCHEMBL1318454 | 0.75 | CTSK (0.48) | CTSSCTSKCTSBCTSLCAPN1 | |
| SCHEMBL19000135 | 0.75 | CTSK (0.48) | CTSSCTSKCTSBCTSLCAPN1 | |
| SCHEMBL6168773 | 0.75 | CTSK (0.48) | CTSSCTSKCTSBCTSLCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656949-B2 | Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis | MERCK PATENT GMBH (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9656949-B2 | Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis | MERCK PATENT GMBH (DE) | 2017-05-23 | — | — | US | disclosed |
| EP-2953932-B1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AS AGGRECANASE INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-2953932-B1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AS AGGRECANASE INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-20150368188-A1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AS AGGRECANASE INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-24 | — | — | US | disclosed |
| US-20150368188-A1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AS AGGRECANASE INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-12-24 | — | — | US | disclosed |
| EP-2953932-A1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AS AGGRECANASE INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Merck Patent GmbH (DE) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014121884-A1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AS AGGRECANASE INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | WO | disclosed |
| WO-2014121884-A1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AS AGGRECANASE INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368188-A1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES AS AGGRECANASE INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS5, ADAMTS1, ADAMTS7 | CTSS 154/4885CTSK 194/4885CTSB 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.